News & Updates
Filter by Specialty:
Is it safe to take olmesartan in combination therapy for advanced hypertension?
Use of olmesartan in combination practice is safe and results in similar cardiovascular composite outcomes, including myocardial infarction (MI), when compared with active comparators in hypertensive patients who need more than two antihypertensive medications, reports a study.
Is it safe to take olmesartan in combination therapy for advanced hypertension?
14 Sep 2023
Wine intake inversely tied to CV outcomes
A systematic review and meta-analysis showed an inverse relationship between wine consumption and the risks of cardiovascular (CV) mortality, CV disease (CVD), and coronary heart disease (CHD).
Wine intake inversely tied to CV outcomes
13 Sep 2023
SHBG levels inversely linked to hypertension in middle-aged adults
Levels of sex hormone-binding globulin (SHBG) show an inverse relationship with the development of hypertension and change in blood pressure (BP) levels, independent of major risk factors, according to a community-based study.
SHBG levels inversely linked to hypertension in middle-aged adults
12 Sep 2023
HEART-FID confirms IV iron safety for HF but falls short in efficacy
The HEART-FID trial narrowly missed its primary endpoint, showing modest improvement in all-cause mortality, heart failure hospitalizations (hHF), and exercise function with ferric carboxymaltose (FCM) in HFrEF* patients with iron deficiency (ID).
HEART-FID confirms IV iron safety for HF but falls short in efficacy
11 Sep 2023
Primary PCI strategy reduces death rates in STEMI patients
Between 2003 and 2018, 1-year mortality has decreased considerably in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) in a high-income European country with a fully implemented primary PCI strategy, reports a study.